EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study

Chengxiang Guo, Weiran Du, Yiwen Chen, Wenbo Xiao, Ke Sun, Yan Shen, Min Zhang, Jian Wu, Shunliang Gao, Jun Yu, Risheng Que, Xing Xue und 2 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70633 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Chengxiang Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China (No.2019YFC1316000).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Standard treatments provide limited benefits for patients with intermediate‐ or advanced‐stage hepatocellular carcinoma (HCC). This retrospective observational study aimed to assess the potential improvements in outcomes associated with systemic therapies in patients receiving transarterial chemoembolization (TACE) for initially unresectable HCC.

Methods

Between February 2019 and March 2023, we reviewed patients diagnosed with intermediate‐to‐advanced HCC who were treated with either TACE or TACE combined with antiangiogenic agents and immune checkpoint inhibitors (combination therapy) as their initial treatment. To address potential confounding biases, patients were further stratified into surgical and non‐surgical cohorts, and separate analyses were conducted. The primary endpoints were progression‐free survival (PFS) and overall survival (OS), with safety profiles also evaluated.

Results

Among 279 patients with initially unresectable intermediate or advanced HCC, 156 successfully underwent curative‐intent liver resection after preoperative treatments (TACE group, n = 69; combination group, n = 87), while 123 patients continued with non‐surgical treatments (TACE group, n = 31; combination group, n = 92). After propensity score matching, 26 matched patient pairs were generated within the non‐surgical cohort. The combination group exhibited significantly improved PFS in non‐surgical patients compared with the TACE group (9.4 vs. 7.2 months, p = 0.043). Cox proportional hazards analysis further confirmed that combination therapy was associated with improved PFS (hazard ratio = 0.476, 95% confidence interval: 0.257–0.883, p = 0.019). For surgical patients exceeding the up‐to‐seven criteria, the combination group demonstrated superior median PFS (18.0 vs. 14.6 months, p = 0.03) and OS (not reached vs. 50.1 months, p = 0.049) compared with the TACE group. Adverse events were manageable, with no treatment‐related fatalities reported.

Conclusion

Combination therapy with TACE demonstrated enhanced survival benefits for patients with intermediate to advanced HCC, particularly in surgical patients with higher tumor burdens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedCombined Modality TherapyImmune Checkpoint InhibitorsAngiogenesis InhibitorsTreatment OutcomeProgression-Free SurvivalAdult

Stichwörter der Autor:innen

combination therapyhepatocellular carcinomasurvivaltransarterial chemoembolization

Substanzen

Immune Checkpoint InhibitorsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
  • Zhejiang Provincial Clinical Research Center for the Study of Hepatobiliary & Pancreatic Diseases, Hangzhou, China.
  • Cancer Center, Zhejiang University, Hangzhou, China.
  • Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Xueli Bai

Förderung

  • National Key Research and Development Program of China (No.2019YFC1316000)

Zitieren

APA

Guo, C., Du, W., Chen, Y., Xiao, W., Sun, K., Shen, Y., Zhang, M., Wu, J., Gao, S., Yu, J., Que, R., Xue, X., Bai, X., & Liang, T. (2025). Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study. Cancer Medicine. https://doi.org/10.1002/cam4.70633

Vancouver

Guo C, Du W, Chen Y, Xiao W, Sun K, Shen Y, et al. Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study. Cancer Medicine. 2025. doi:10.1002/cam4.70633

BibTeX
@article{Guo2025,
  author = {Guo, Chengxiang and Du, Weiran and Chen, Yiwen and Xiao, Wenbo and Sun, Ke and Shen, Yan and Zhang, Min and Wu, Jian and Gao, Shunliang and Yu, Jun and Que, Risheng and Xue, Xing and Bai, Xueli and Liang, Tingbo},
  title = {Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70633}
}
Kostenlos starten →